GalaxyTerpenes
Two groundbreaking studies on psychedelics prove exciting breakthroughs are emerging in the fight against Alcohol Use Disorder (AUD). These studies are sparking hope for innovative treatments that could reshape the way addiction treatment is approached.
The first study focuses on the effects of psilocybin, a powerful psychedelic compound. Researchers found that a single dose of psilocybin, specifically 25 milligrams, significantly reduced alcohol consumption in adults with severe AUD. This open-label study, involving 10 participants, revealed most individuals craved alcohol less and consumed fewer drinks during a 12-week period. The study also revealed that participants felt more confident in their ability to abstain from alcohol.
Coauthored by Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), the research highlights the potential benefits of psilocybin in treating AUD. Notably, the study found that most participants reduced their daily alcohol intake and experienced fewer heavy drinking days. Although the study had limitations, such as a small sample size and the lack of a control group, the results align with existing evidence supporting psilocybin’s potential to reduce alcohol cravings and improve self-efficacy.
LSD adds additional hope for Alcohol Use Disorder
A separate study published in the journal Progress in Neuro-Psychopharmacology and Biological Psychiatry analyzed previous research on classic psychedelics like psilocybin and LSD. This was subsequently reported in Marijuana Moment. That study concluded that these substances show promise in treating drug addiction, particularly Alcohol Use Disorder, by modulating brain neuroplasticity. However, the study also cautioned that psychedelic-assisted treatments may not work for everyone, highlighting the need for further research to explore different doses and protocols.
These findings add to the growing body of evidence suggesting psychedelics could revolutionize addiction treatment. The National Institutes of Health (NIH) recently announced a $2.4 million grant to fund research on using psychedelics to treat methamphetamine use disorders. This demonstrates the government’s increasing interest in this promising field.
As more studies explore the potential of psychedelics in treating addiction, the future looks bright for those struggling with AUD. With continued research and funding, psychedelics may soon play a key role in transforming addiction therapy.
You might also enjoy
None of the statements herein have been evaluated by the FDA. Furthermore, none of the statements herein should be construed as dispensing medical advice or making claims regarding the cure of diseases. You should consult a licensed health care professional before starting any supplement, dietary, or exercise program, especially if you are pregnant or have any pre-existing injuries or medical conditions. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any diseases.